STEMINENT BIOTHERAPEUTICS INC has a total of 12 patent applications. It decreased the IP activity by 83.0%. Its first patent ever was published in 2013. It filed its patents most often in Taiwan, China and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and basic materials chemistry are ZHANG MINGDE, HUBEI KETIAN PHARMACEUTICAL CO LTD and TRITICUM EXPLOITATIE B V.
# | Country | Total Patents | |
---|---|---|---|
#1 | Taiwan | 4 | |
#2 | China | 2 | |
#3 | United States | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | EPO (European Patent Office) | 1 | |
#6 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Basic materials chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Preservation of human bodies |
# | Name | Total Patents |
---|---|---|
#1 | Ong Wei-Kee | 8 |
#2 | Ho Jennifer Hui-Chun | 7 |
#3 | Chang Ryan | 7 |
#4 | Lai Hsiu-Yu | 4 |
#5 | Liang Yin | 3 |
#6 | Wu Yu-Shan | 3 |
#7 | Cheng Cheng-Yi | 3 |
#8 | Ho Hui-Chun | 3 |
#9 | Lee Oscar Kuang-Sheng | 3 |
#10 | Ong Wei Kee | 2 |
Publication | Filing date | Title |
---|---|---|
WO2019050546A2 | Methods for treatment and prevention of acute liver failure | |
TW201900205A | A therapy for polyglutamine (polyq) diseases | |
KR20200001598A | Treatment for Polyglutamine (POLYQ) Disease | |
TW201538728A | Quadri-positive stromal cell (qpsc) population for superior cell protection and immunomodulation | |
CN104336005A | Blood bag gradually-freezing preservation device and application method thereof | |
TW201504439A | Cryopreservation storage device for blood bag and using method thereof |